Last update July 22, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
S-(Fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate is Fluticasone in Chemical name.
Is written in other languages:S-(Fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate is also known as
S-(Fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate belongs to these groups or families:
Main tradenames from several countries containing S-(Fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | oral: 1; inhal: 6 -18 | % |
Molecular weight | 500 | daltons |
Protein Binding | > 99 | % |
VD | 4.2 - 8.6 | l/Kg |
pKa | 12.19 | - |
Tmax | 0.25 - 1 | hours |
T½ | 7.8 - 15.1 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a potent glucocorticoid used inhaled for asthma, nasally for rhinitis and polyps and applied topically on various skin disorders.
At latest update no relevant data on this subject were found in connection with breastfeeding.
Its pharmacokinetic characteristics (low systemic absorption, moderately elevated molecular weight, high plasma protein binding and large volume of distribution), make it highly unlikely that significant quantities will pass into breast milk. (Chambers 2021)
Its low oral bioavailability protects the infant from intestinal absorption.
Directly administered in childhood, only prolonged treatment with high doses of fluticasone can affect pituitary-adrenal function and growth. (Allen 2020, Todd 2002 & 1996)
Another similar inhaled corticosteroid (Budesonide) is excreted in breast milk in negligible amounts.
Several medical societies and expert authors consider topical, systemic or inhaled steroid medication to be safe or probably compatible with breastfeeding. (Hale, LactMed, Middleton 2020, Briggs 2015, Schaefer 2015, Amir 2011, National Asthma 2004, Ellsworth 1994)
TOPICAL USE:
Whenever a treatment for nipple eczema or dermatitis is required, the lowest potency steroid compound should be used. It should be applied right after the feed to make sure it has disappeared before the next nursing. Otherwise, wipe cream out with a clean gauze. Do not continuously use for longer than a week. Reportedly, a case of mineral-steroid toxicity has occurred due to continuous use of cream on the nipple. (De Stefano 1983)
Creams, gels or similar products that contain paraffin or mineral oil should not be used on the nipple to avoid absorption by the infant.(Concin 2008, Noti 2003)